Joaquim Bellmunt, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA, talks on the role of adjuvant immunotherapy in oncology. Recently, the phase 3 KEYNOTE-564 trial (NCT03142334) showed a benefit for patients with renal cell carcinoma (RCC) treated with pembrolizumab adjuvant therapy. In addition, nivolumab was recently approved by the FDA for adjuvant treatment of urothelial carcinoma (UC). Adjuvant immunotherapy has also been shown to be effective to treat other solid tumors, especially during early-stage cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

свернуть